Skip to main content
. Author manuscript; available in PMC: 2014 Sep 19.
Published in final edited form as: Cochrane Database Syst Rev. 2011 Jan 19;(1):CD006626. doi: 10.1002/14651858.CD006626.pub2
Trial name or title Trial 10769
F1D-US-HGMN
Methods Allocation: random, no further details.
Blindness.: double, no further details.
Duration: 12 weeks.
Design: parallel.
Location: not reported.
Participants Diagnosis: schizophrenia or schizoaffective disorder or schizophreniform disorder. N=not reported.
Sex: not reported. M, not reported. F.
Age: 18-65 years.
History: duration ill not reported., age at onset not reported.
Setting: not reported.
Interventions

  1. Olanzapine: fixed/flexible dose: not reported. Allowed dose range: not reported. Mean dose: not reported. N=not reported.

  2. Risperidone: fixed/flexible dose: not reported. Allowed dose range: not reported. Mean dose: not reported. N=not reported
Outcomes Global state: Response, remission.
Mental State: PANSS.
Service use: Psychiatric hospitalisations.
Adverse effects.
Starting date June 2006
Contact information not reported.
Notes